Hair Care
GLP-1 Drugs and Bone Density
Studies on GLP-1 medication and bone health genuinely disagree with each other. Here is why, and what that means for any...
Semaglutide is now being formally studied as a treatment for alcohol use disorder, separate from its weight loss use entirely. The early results are genuinely interesting, and understanding why connects directly to the reward-pathway mechanism covered elsewhere in this series.
The trial
A randomised clinical trial titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder was a phase 2, double-blind, parallel-arm study conducted over 9 weeks at a US academic medical centre, enrolling 48 participants, most of whom were not actively seeking treatment for their drinking.
Low-dose semaglutide reduced the amount of alcohol consumed during a post-treatment laboratory self-administration task, and significantly reduced weekly alcohol craving relative to placebo.
A separate trial using oral semaglutide specifically in treatment-seeking adults with alcohol use disorder found consistent results, reinforcing that this was not a finding specific to one formulation or one type of participant.
Why this connects to weight loss research
This is not an unrelated tangent. It reflects the same underlying question this series has covered regarding food noise and reward-pathway involvement in eating.
GLP-1 receptors are present not only in the gut and appetite-regulating brain regions but also in areas involved in reward processing generally, including regions implicated in substance use. The theory driving this research is that GLP-1 pathway activation may reduce reward-seeking behaviour more broadly, not only in relation to food.
If that holds up in larger trials, it would mean the mechanism reducing food preoccupation and the mechanism potentially reducing alcohol craving are, at least partially, the same underlying system.
What this is not
Worth being precise about the current state of the evidence.
This is not an approved use. GLP-1 medications are not approved for alcohol use disorder. This remains investigational, based on early-phase trials with modest sample sizes.
It is not a substitute for established alcohol use disorder treatment. Existing evidence-based treatments, including counselling and, where appropriate, medications specifically approved for this purpose, remain the standard of care.
The trials involved participants primarily seeking help for other things or with less severe alcohol use disorder in some cases, so how this generalises to more severe dependence is not yet established.
What people already on these drugs for weight loss report
Separate from the formal trials, this connects to something frequently mentioned informally by people taking GLP-1 medication for weight management.
Reduced interest in alcohol is a commonly reported observation among people on these drugs for weight loss specifically, even though weight loss was the reason for starting treatment rather than alcohol reduction. This informal pattern is consistent with, and likely part of the motivation behind, the formal trials now underway.
Why this matters practically, right now
Setting aside the investigational alcohol use disorder research, there is a practical point worth making for anyone currently taking GLP-1 medication for weight loss.
Alcohol and GLP-1 medication have their own direct interaction, separate from any craving-reduction effect. Alcohol impairs the liver's ability to raise blood sugar, and GLP-1 medication can lower it, particularly in combination with insulin or sulfonylureas covered in our guide to drug interactions with GLP-1 medication. Alcohol also irritates the stomach, compounding nausea that is already a common side effect.
So if you notice reduced desire to drink while on appetite medication, that observation does not change the direct pharmacological caution around combining alcohol with these drugs regardless.
If alcohol use is a genuine concern
This is worth stating plainly, separate from the weight loss context entirely.
If you are drinking in a way that concerns you, or that others have raised concern about, that deserves proper assessment rather than hoping a weight loss medication addresses it incidentally. Alcohol use disorder is a recognised, treatable condition, and speaking with a specialist about it directly is the appropriate route, regardless of whether weight is also a factor.
Where this leaves appetite support
GLP-1 appetite support you hold under the tongue works on the GLP-1 pathway as a physician-reviewed sublingual supplement with physician review before dispatch. METASLIM™ is not a pharmaceutical GLP-1 receptor agonist, is not studied for alcohol use disorder, and the trial findings in this article describe pharmaceutical semaglutide specifically rather than this product.
The relevant, honest connection is mechanistic interest rather than a treatment claim. Our guide to GLP-1 and food noise covers the reward-pathway involvement in eating specifically, which this alcohol research parallels.
The summary
A randomised trial found semaglutide reduced both alcohol consumption in a laboratory task and self-reported weekly craving compared with placebo, in adults with alcohol use disorder.
A separate oral semaglutide trial in treatment-seeking participants found consistent results.
This research is investigational, not an approved use, and does not replace established alcohol use disorder treatment.
The proposed mechanism connects to the same reward-pathway signalling covered in this series regarding food noise, since GLP-1 receptors are present in brain regions involved in reward processing generally.
Alcohol still carries its own direct interaction caution with GLP-1 medication regardless of any craving-reduction effect, given blood sugar and stomach irritation risks.
See if you qualify for the program if appetite is your concern, and speak to a specialist directly if alcohol use is a separate worry.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.